Skip to main content
Premium Trial:

Request an Annual Quote

Genzyme Molecular Oncology Files for IPO


CAMBRIDGE, Mass--Genzyme Molecular Oncology, the Genzyme division that develops gene-based approaches to cancer therapy and diagnosis, announced April 28 that it had filed a registration statement with the US Securities and Exchange Commission for an initial public offering of 3 million shares of common stock. The company also granted underwriters a 30-day option to buy up to 450,000 additional shares to cover over-allotments.

The company stated that it anticipated the initial public offering stock price to be between $9 and $11 per share. Genzyme Molecular employs an integrated approach to translating information gained through its genomics capabilities into gene therapy, small molecule therapeutics, and genetic diagnostics.

Filed under

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.